Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引：0

作者：

Kexuan Li

Fuqiang Zhao

Yuchen Guo

Qingbin Wu

Shuangling Luo

Junling Zhang

Heli Li

Shidong Hu

Bin Wu

Guole Lin

Huizhong Qiu

Beizhan Niu

Xiyu Sun

Lai Xu

Junyang Lu

Xiaohui Du

Zheng Wang

Xin Wang

Liang Kang

Ziqiang Wang

Quan Wang

Qian Liu

Yi Xiao

机构：

[1] Peking Union Medical College Hospital,Division of Colorectal Surgery, Department of General Surgery

[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Colorectal Surgery

[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Gastrointestinal Surgery, General Surgery Center

[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Colorectal Cancer Center, Department of General Surgery

[5] The First Hospital of Jilin University,Department of General Surgery (Colorectal Surgery)

[6] West China Hospital,Biomedical Innovation Center

[7] Sichuan University,Department of Gastrointestinal Surgery

[8] The Sixth Affiliated Hospital,Department of Gastrointestinal Surgery

[9] Sun Yat-sen University,Department of General Surgery, The First Medical Center

[10] Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases,undefined

[11] The Sixth Affiliated Hospital,undefined

[12] Sun Yat-sen University,undefined

[13] The Sixth Affiliated Hospital,undefined

[14] Sun Yat-sen University,undefined

[15] Peking University First Hospital,undefined

[16] Union Hospital,undefined

[17] Tongji Medical College,undefined

[18] Huazhong University of Science and Technology,undefined

[19] Chinese People’s Liberation Army (PLA) General Hospital,undefined

来源：

BMC Cancer | / 23卷 / 1期

关键词：

Colon cancer; High-risk pathological features; Adjuvant chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 92 条

[1]

André T(2015)Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study J Clin Oncol 33 4176-4187

[2]

de Gramont A(2011)Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer J Clin Oncol 29 1465-1471

[3]

Vernerey D(2016)Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study J Natl Compr Canc Netw 14 47-56

[4]

Haller DG(2004)American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 3408-3419

[5]

Tabernero J(2018)A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial Eur J Cancer 96 54-63

[6]

Maroun J(2020)Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study J Surg Res 252 69-79

[7]

Booth CM(2022)Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201) BMC Cancer 22 170-1692

[8]

Nanji S(2018)Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas Am J Surg Pathol 42 1686-118

[9]

Wei X(2012)MissForest–non-parametric missing value imputation for mixed-type data Bioinformatics 28 112-236

[10]

Benson AB(2007)Test for Additive Interaction in Proportional Hazards Models Ann Epidemiol 17 227-609

← 1 2 3 4 5 6 7 8 9 10 →